RECRUITING

Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Talk to us

Conditions

Autism Spectrum DisorderAutismAsperger Syndrome

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Investigating the efficacy of a form of TMS called theta-burst stimulation for restricted and repetitive behavior in ASD.

Official Title

Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Quick Facts

Study Start:2021-01-04
Study Completion:2027-03-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04532424

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Diagnosis of Autism Spectrum Disorder (ASD), Asperger's or Autism.
  2. 2. Meet criteria for ASD on clinical assessments (ADOS-2 or CARS/BOSA if conducted remotely \& ADI-R)
  3. 3. Aged between 12-45 years old
  4. 4. Have a reliable informant who can complete relevant questionnaires
  5. 5. Must have previously not responded or not tolerated 2 treatments.
  1. 1. Any contraindications for TMS e.g. history of seizures
  2. 2. Pregnancy
  3. 3. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
  4. 4. Active substance use (\<1 week) or intoxication verified by toxicology screen--of cocaine, amphetamines, benzodiazepines
  5. 5. Showing symptoms of withdrawal from alcohol or benzodiazepines
  6. 6. DSM-5 diagnosis of bipolar disorder or a psychotic disorder e.g. schizophrenia.
  7. 7. Significant sensory impairments such as blindness or deafness.
  8. 8. Any other indication the PI feels would comprise data
  9. 9. Current severe insomnia (must sleep a minimum of 4 hours the night before stimulation)
  10. 10. IQ\<50 or not testable using IQ measures and no historical IQ score available
  11. 11. Currently taking Clozapine or another medication that the PI determines increases the risk of TMS or may disrupt the efficacy.
  12. 12. A motor threshold that is too high to allow safe/tolerable treatment.

Contacts and Locations

Study Contact

Briana Hernandez
CONTACT
(650) 736-1235
autismdd@stanford.edu

Principal Investigator

Antonio Y. Hardan, MD
PRINCIPAL_INVESTIGATOR
Stanford University

Study Locations (Sites)

Stanford University
Stanford, California, 94305-5719
United States

Collaborators and Investigators

Sponsor: Stanford University

  • Antonio Y. Hardan, MD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-01-04
Study Completion Date2027-03-01

Study Record Updates

Study Start Date2021-01-04
Study Completion Date2027-03-01

Terms related to this study

Additional Relevant MeSH Terms

  • Autism Spectrum Disorder
  • Autism
  • Asperger Syndrome